Adrenocortical Carcinoma: Stable Incidence, Improved Stage IV Survival

The outlook for patients diagnosed with adrenocortical carcinoma (ACC), a rare and aggressive cancer of the adrenal gland, is showing signs of improvement, particularly for those with advanced disease. Whereas the overall incidence of ACC remains relatively stable, a recent analysis indicates that survival rates for stage IV ACC have increased, linked to the growing practice of centralising care at specialist centres.

Adrenocortical carcinoma affects approximately 1-2 people per million each year, and is more frequently diagnosed in women, accounting for 55-65% of cases, compared to 35-45% in men. As detailed in The Lancet Diabetes & Endocrinology, this cancer presents unique challenges for clinicians, requiring management of both the tumor’s growth and the hormonal imbalances it can cause, significantly impacting a patient’s life expectancy.

Understanding Adrenocortical Carcinoma

The adrenal glands, located above the kidneys, produce essential hormones like cortisol and aldosterone. ACC develops when abnormal cells within the adrenal cortex – the outer layer of the gland – begin to grow uncontrollably. These tumors can be functional, meaning they produce excess hormones, or non-functional. Hormone overproduction can lead to a range of symptoms, including Cushing’s syndrome (caused by excess cortisol), virilization in women (development of male characteristics due to excess androgens), or feminization in men (development of female characteristics due to excess estrogens).

Early-stage ACC is typically treated with surgical removal of the tumor. Contemporary approaches to treatment emphasize open surgery as the standard of care, whereas minimally invasive techniques may be considered for smaller tumors without signs of local spread. Though, ACC often presents at a later stage, making complete surgical removal more difficult.

The Impact of Centralised Care

The recent improvements in survival for stage IV ACC, as highlighted by Medscape, are largely attributed to the increasing trend of centralising care. This means that patients are referred to specialist centres with expertise in diagnosing and treating ACC, allowing for a more coordinated and comprehensive approach.

Centralisation allows for multidisciplinary teams – including surgeons, oncologists, endocrinologists, and radiologists – to collaborate on treatment plans. It also facilitates access to clinical trials and novel therapies. The benefits of specialist care extend beyond surgery, encompassing medical therapies like mitotane, etoposide, and cisplatin, as well as participation in research initiatives aimed at improving outcomes.

What the Data Reveals – and Doesn’t

While the Medscape report points to improved survival, it’s important to understand the limitations of the data. The analysis doesn’t detail the specific survival rates achieved, nor does it specify the length of follow-up for patients. The study doesn’t explore the reasons why centralisation improves survival – is it due to better surgical techniques, more effective medical therapies, or simply earlier and more accurate diagnosis?

It’s also crucial to remember that ACC remains a rare cancer, and data on long-term survival are limited. The observed improvements may be influenced by changes in diagnostic practices or treatment protocols over time, making it difficult to isolate the specific impact of centralisation. The report also doesn’t address potential disparities in access to specialist care based on geographic location or socioeconomic status.

Navigating Advanced Disease

For patients with advanced ACC that cannot be completely removed surgically, treatment options are more limited. Traditional chemotherapy regimens have shown modest benefit, and the response rates are often low. However, ongoing research is exploring new therapeutic strategies, including targeted therapies and immunotherapies.

Mitotane, a drug that selectively destroys adrenal cortical cells, remains a cornerstone of treatment for ACC. However, it has significant side effects, including adrenal insufficiency and neurological complications. Clinical trials are investigating the use of mitotane in combination with other agents to enhance its effectiveness and reduce its toxicity.

The Role of Ongoing Surveillance

Given the rarity of ACC and the challenges in diagnosing and treating it, ongoing surveillance and research are essential. Healthcare professionals are encouraged to maintain a high index of suspicion for ACC in patients presenting with unexplained hormonal imbalances or adrenal masses.

Further research is needed to identify biomarkers that can predict the risk of ACC development and progression. This could lead to earlier detection and more personalised treatment strategies. Studies are needed to evaluate the long-term effects of different treatment regimens and to identify ways to improve the quality of life for patients with ACC.

Looking Ahead: The future of ACC treatment hinges on continued collaboration between specialist centres, participation in clinical trials, and a commitment to ongoing research. For patients and their families, seeking care from experienced ACC specialists is paramount, and staying informed about the latest advances in treatment is crucial.